MCID: DYS009
MIFTS: 49

Dysthymic Disorder

Categories: Mental diseases

Aliases & Classifications for Dysthymic Disorder

MalaCards integrated aliases for Dysthymic Disorder:

Name: Dysthymic Disorder 12 43 15 17 71
Dysthymia 12 74 54 15 32

Classifications:



External Ids:

Disease Ontology 12 DOID:12139
ICD9CM 34 300.4
MeSH 43 D019263
NCIt 49 C34562
SNOMED-CT 67 78667006
ICD10 32 F34.1
UMLS 71 C0013415

Summaries for Dysthymic Disorder

Disease Ontology : 12 A mood disorder that involves the presence of a low mood almost daily over a span of at least two years.

MalaCards based summary : Dysthymic Disorder, also known as dysthymia, is related to neurotic disorder and depression. An important gene associated with Dysthymic Disorder is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Serotonergic synapse and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Testosterone and Testosterone undecanoate have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 74 Dysthymia, also known as persistent depressive disorder (PDD), is a mood disorder consisting of the same... more...

Related Diseases for Dysthymic Disorder

Diseases related to Dysthymic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
# Related Disease Score Top Affiliating Genes
1 neurotic disorder 31.1 SLC6A4 MAOA HTR2A HTR1A BDNF
2 depression 31.0 SLC6A4 MAOA HTR2A HTR1A DISC2 BDNF
3 personality disorder 30.9 SLC6A4 MAOA HTR2A HTR1A BDNF
4 cyclothymic disorder 30.9 PIR HTR2A CGAS
5 avoidant personality disorder 30.8 WASF2 WASF1 SLC6A4 PIR MAOA
6 separation anxiety disorder 30.6 WASF2 WASF1 SLC6A4 PROC CGAS
7 somatization disorder 30.6 SLC6A4 SCLY HTR2A
8 generalized anxiety disorder 30.4 SLC6A4 PRODH MAOA HTR2A HTR1A BDNF
9 cannabis abuse 30.3 WASF2 WASF1 BDNF
10 major depressive disorder 30.3 SLC6A4 MAOA LIPA HTR2A HTR1A HCRT
11 panic disorder 30.3 SLC6A4 MAOA HTR2A HTR1A BDNF
12 obsessive-compulsive disorder 30.3 SLC6A4 MAOA HTR2A HTR1A BDNF
13 mood disorder 30.2 SLC6A4 PRODH MAOA HTR2A HTR1A DISC2
14 chronic fatigue syndrome 30.2 SLC6A4 MAOA HTR2A HTR1A
15 bulimia nervosa 30.1 SLC6A4 MAOA HTR2A BDNF
16 alcohol use disorder 30.1 WASF2 WASF1 SLC6A4 HTR2A HTR1A BDNF
17 eating disorder 30.1 SLC6A4 HTR2A HCRT BDNF
18 bipolar i disorder 30.1 SLC6A4 HTR2A HTR1A BDNF
19 attention deficit-hyperactivity disorder 30.1 SLC6A4 PRODH MAOA HTR2A HTR1A BDNF
20 schizoid personality disorder 30.1 WASF2 WASF1 PROC PIR
21 irritable bowel syndrome 30.0 SLC6A4 HTR2A HTR1A BDNF
22 schizotypal personality disorder 30.0 WASF2 WASF1 PRODH PIR
23 anxiety 30.0 SLC6A4 PRODH MAOA HTR2A HTR1A HCRT
24 melancholia 30.0 SLC6A4 MAOA HTR2A HTR1A BDNF
25 obsessive-compulsive personality disorder 30.0 WASF2 WASF1 SLC6A4 PIR HTR2A
26 borderline personality disorder 30.0 SLC6A4 MAOA HTR2A HTR1A BDNF
27 alcohol dependence 29.9 SLC6A4 MAOA HTR2A HTR1A HCRT BDNF
28 constipation 29.9 SLC6A4 HTR2A HTR1A BDNF
29 sleep disorder 29.9 SLC6A4 HTR2A HTR1A HCRT BDNF
30 endogenous depression 29.9 WASF1 SLC6A4 SCLY MAOA LIPA HTR2A
31 bipolar disorder 29.8 SLC6A4 PRODH MAOA HTR2A HTR1A DISC2
32 anorexia nervosa 29.7 SLC6A4 MAOA HTR2A HTR1A HCRT BDNF
33 atypical depressive disorder 29.6 SLC6A4 SERPINA3 MAOA HTR2A HTR1A BDNF
34 dementia 29.5 SERPINA3 HTR2A HTR1A HCRT BDNF
35 mental depression 29.4 WASF2 WASF1 SLC6A4 SERPINA3 SCLY PRODH
36 antisocial personality disorder 29.3 WASF2 WASF1 SLC6A4 PIR MAOA HTR2A
37 hypochondriasis 29.3 SLC6A4 PIR IVL HTR2A HTR1A CFI
38 migraine with or without aura 1 29.2 SLC6A4 MAOA HTR2A HTR1A HCRT EHD4
39 adjustment disorder 29.1 SLC6A4 SCLY HTR2A HTR1A HCRT CGAS
40 schizophrenia 29.0 SLC6A4 SERPINA3 PRODH MAOA HTR2A HTR1A
41 oppositional defiant disorder 28.9 WASF3 WASF2 WASF1 SLC6A4 PROC MAOA
42 psychotic disorder 28.9 SLC6A4 SERPINA3 PRODH MAOA HTR2A HTR1A
43 phobia, specific 28.7 WASF2 WASF1 SLC6A4 PRODH PROC MAOA
44 social phobia 28.7 WASF2 WASF1 SLC6A4 SERPINA3 PRODH MAOA
45 substance abuse 28.4 WASF3 WASF2 WASF1 SLC6A4 SERPINA3 PRODH
46 pyromania 10.4 WASF1 MAOA
47 alcoholic psychosis 10.4 SLC6A4 HTR2A
48 voyeurism 10.4 PRODH MAOA
49 brunner syndrome 10.4 SLC6A4 MAOA HTR2A
50 cataract 25 10.4 WASF3 WASF1

Comorbidity relations with Dysthymic Disorder via Phenotypic Disease Network (PDN): (show top 50) (show all 52)


Active Peptic Ulcer Disease Acute Cystitis
Adjustment Disorder Anxiety
Atrophic Gastritis Atypical Depressive Disorder
Avoidant Personality Disorder Benign Essential Hypertension
Borderline Personality Disorder Bronchitis
Chronic Pulmonary Heart Disease Conversion Disorder
Deficiency Anemia Delusional Disorder
Dependent Personality Disorder Dyskinesia of Esophagus
Esophagitis Familial Atrial Fibrillation
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Histrionic Personality Disorder
Hypertension, Essential Hypochondriasis
Hypothyroidism Intermediate Coronary Syndrome
Iron Deficiency Anemia Irritable Bowel Syndrome
Major Depressive Disorder Mitral Valve Disease
Mood Disorder Narcissistic Personality Disorder
Obsessive-Compulsive Disorder Obsessive-Compulsive Personality Disorder
Opioid Addiction Oral Candidiasis
Osteoarthritis Osteoporosis
Paralytic Ileus Parkinson Disease, Late-Onset
Peripheral Vascular Disease Personality Disorder
Postinflammatory Pulmonary Fibrosis Post-Traumatic Stress Disorder
Postural Orthostatic Tachycardia Syndrome Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder
Social Phobia Somatization Disorder

Graphical network of the top 20 diseases related to Dysthymic Disorder:



Diseases related to Dysthymic Disorder

Symptoms & Phenotypes for Dysthymic Disorder

MGI Mouse Phenotypes related to Dysthymic Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.77 BDNF CGAS HCRT HTR1A HTR2A LIPA
2 homeostasis/metabolism MP:0005376 9.44 BDNF CFI CGAS EHD4 HCRT HTR1A

Drugs & Therapeutics for Dysthymic Disorder

Drugs for Dysthymic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
2
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
3
Methyltestosterone Approved Phase 4 58-18-4 6010
4
Testosterone enanthate Approved Phase 4 315-37-7 9416
5
Citalopram Approved Phase 4 59729-33-8 2771
6
Imipramine Approved Phase 4 50-49-7 3696
7
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
8
Sodium citrate Approved, Investigational Phase 4 68-04-2
9
Memantine Approved, Investigational Phase 4 19982-08-2 4054
10
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
11
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
12
Donepezil Approved Phase 4 120014-06-4 3152
13
Norepinephrine Approved Phase 4 51-41-2 439260
14
Sertraline Approved Phase 4 79617-96-2 68617
15
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
16 Testosterone 17 beta-cypionate Phase 4
17 Hormones Phase 4
18 Antineoplastic Agents, Hormonal Phase 4
19 Hormone Antagonists Phase 4
20 Anabolic Agents Phase 4
21 Monoamine Oxidase Inhibitors Phase 4
22 Parasympatholytics Phase 4
23 Muscarinic Antagonists Phase 4
24 Cholinergic Antagonists Phase 4
25 Antiparkinson Agents Phase 4
26 Venlafaxine Hydrochloride Phase 4
27 Citrate Phase 4
28 Phosphodiesterase 5 Inhibitors Phase 4
29 Phosphodiesterase Inhibitors Phase 4
30 Vasodilator Agents Phase 4
31 Sildenafil Citrate Phase 4 171599-83-0
32 Excitatory Amino Acid Antagonists Phase 4
33 Cholinesterase Inhibitors Phase 4
34 Duloxetine Hydrochloride Phase 4
35 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
36 Analgesics Phase 4
37
Histamine Approved, Investigational Phase 2, Phase 3 51-45-6 774
38
Lithium carbonate Approved Phase 2, Phase 3 554-13-2
39
Ethanol Approved Phase 3 64-17-5 702
40
Vortioxetine Approved, Investigational Phase 3 508233-74-7 9966051
41
Cocaine Approved, Illicit Phase 3 50-36-2 446220 5760
42
tannic acid Approved Phase 3 1401-55-4
43
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
44
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
45 Adrenergic alpha-Antagonists Phase 2, Phase 3
46 Anti-Anxiety Agents Phase 2, Phase 3
47 Histamine H1 Antagonists Phase 2, Phase 3
48
Histamine Phosphate Phase 2, Phase 3 51-74-1 65513
49 Histamine Antagonists Phase 2, Phase 3
50 Serotonin 5-HT3 Receptor Antagonists Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 111)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Testosterone Replacement in Treating Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
2 Double-Blind Treatment of Outpatients With Dysthymic Disorder With Wellbutrin XL Completed NCT00225251 Phase 4 bupropion XL
3 Duloxetine for Chronic Depression: a Double-blind Study Completed NCT00360724 Phase 4 Duloxetine (Cymbalta)
4 An Open Treatment Trial of Duloxetine in Elderly Patients With Dysthymic Disorder Completed NCT01852383 Phase 4 Duloxetine
5 Combined Escitalopram/Bupropion as First Line Treatment for Depression, a Replication. Completed NCT00296712 Phase 4 escitalopram + bupropion
6 Desvenlafaxine (Pristiq) vs. Placebo in the Treatment of Chronic Depression Completed NCT01537068 Phase 4 Desvenlafaxine;Placebo
7 Medication Treatment Following Neuropsychologic, Dichotic and f-MRI Tests in Depressed Outpatients With Repeat f-MRI Following Treatment Completed NCT00296777 Phase 4 Escitalopram;Bupropion;Imipramine
8 Double-Blind Placebo-Controlled Study of Escitalopram in the Treatment of Dysthymic Disorder Completed NCT00220701 Phase 4 Lexapro (escitalopram)
9 A Controlled Trial of Venlafaxine XR for Major Depression After Spinal Cord Injury: A Multi-site Study Completed NCT00592384 Phase 4 venlafaxine XR;placebo
10 Escitalopram vs. Sertraline in the Treatment of Dysthymic Disorder and Double Depression Completed NCT00234312 Phase 4 escitalopram and sertraline
11 Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Major Depressive Disorder or Dysthymic Disorder Completed NCT00518986 Phase 4 armodafinil;placebo
12 A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression Completed NCT00296699 Phase 4 Duloxetine
13 A Multi-Center, Flexible Dose Study With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Evaluate The Impact Of Treatment With Sildenafil Citrate On The Symptoms Of Depression And Quality Of Life (Qol) Of Male Patients With Erectile Dysfunction (ED) Completed NCT00159809 Phase 4 Viagra (Sildenafil citrate)
14 Attenuation of Corticosteroid Induced Hippocampal Changes Completed NCT01656187 Phase 4 Memantine 10 mg capsule;Memantine-matched Placebo capsule
15 Antidepressant Treatment at an Inner City Asthma Clinic Completed NCT01324700 Phase 4 High severity group: Escitalopram;High severity group: Placebo;Low severity group: Escitalopram;Low severity group: Placebo
16 A Pilot Study to Treat Emotional Disorders in Primary Care With Evidence-based Psychological Techniques: A Randomized Controlled Trial Completed NCT01903096 Phase 4 Primary Care Treatment As Usual
17 Pilot Combination Treatment Trial of Mild Cognitive Impairment With Depression Completed NCT01658228 Phase 4 Donepezil;Placebo;Citalopram;Venlafaxine
18 Single-Site, Double-Blind, Flexible-Dose, Placebo-Controlled Study of the Efficacy, Tolerability, & Safety of Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
19 Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults Active, not recruiting NCT01973283 Phase 4 Antidepressant Medication
20 Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction Terminated NCT00398632 Phase 4 Duloxetine
21 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
22 A Comparison of Medication Augmentation and Problem Solving Therapy Withdrawn NCT01942187 Phase 4 Aripiprazole;Bupropion
23 Efficacy and Cost-Effectiveness of 18-Months of Antidepressive Medication Plus Either Cognitive-Behavior Therapy or Dynamic Psychotherapy Compared to Supportive Clinical Management for Recurrent Major Depression: a Pilot Study Unknown status NCT00220623 Phase 3 antidepressant medications, flexible drug choice
24 A Stepped Care Model of Adolescent Depression Treatment in Primary Care Completed NCT01443715 Phase 2, Phase 3
25 An Open Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior Completed NCT01447602 Phase 3
26 Treatment of Adolescent Suicide Attempters (TASA) Completed NCT00080158 Phase 2, Phase 3 fluoxetine;sertraline;citalopram;escitalopram;bupropion;mirtazapine;venlafaxine;lithium
27 A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder Completed NCT00707980 Phase 3 Vortioxetine
28 A Proof of Concept Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders Completed NCT01979133 Phase 3 Icariin
29 Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment Completed NCT01876823 Phase 2, Phase 3 es-citalopram;Memantine
30 A Single-Blind Prospective Study of Quetiapine for the Treatment of Mood Disorders in Adolescents Completed NCT00221468 Phase 3 quetiapine
31 ASCEND: A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression Completed NCT02358343 Phase 3 Antidepressant Drug Therapy
32 A Pilot Study -- An Open-Label, Rater-blinded, Flexible-dose, 8-week Trial of Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features. Completed NCT00610506 Phase 3 Escitalopram
33 A Phase 3 Double Blind, Randomized, Placebo Controlled, Cross-Over Trial to Asses the Efficacy of CALPXT96™in Improving Sleep Quality in Patients With Chronic Non-cancer Pain Withdrawn NCT02232256 Phase 3 CALPXT96
34 Dichotic Listening as a Predictor of Placebo and Medication Response in Depression Completed NCT00296725 Phase 1, Phase 2 Fluoxetine;Imipramine
35 Group IPT for Women Prisoners With Comorbid Substance Use and Depression Completed NCT00606996 Phase 2
36 The Efficacy of Parent Involvement in the Treatment of Adolescent Depression Completed NCT00883519 Phase 1, Phase 2
37 A Double-Blind, Placebo-Controlled Study Examining The Safety, Efficacy, and Tolerability of SEP-225289 in Subjects With Major Depressive Disorder (Including Atypical and Melancholic Features) Completed NCT00584974 Phase 2 SEP-225289;SEP-225289;Venlafaxine;placebo
38 Engagement and Alliance in CBT for Depressed Adolescents Completed NCT00073359 Phase 1, Phase 2
39 Group Interpersonal Psychotherapy for Depressed Adolescents (IPT-AG) in School-based Clinics Completed NCT00270244 Phase 2
40 New Approaches to Cocaine Abuse Medications (A) Completed NCT00000271 Phase 2 Desipramine;Placebo
41 Bringing What Works to Youth in Prison: An Evidence-Based Trauma Intervention Completed NCT01560728 Phase 1, Phase 2
42 A Phase 2a Study to Evaluate the Kappa Opioid Receptor As a Target for the Treatment of Mood and Anxiety Spectrum Disorders by Evaluation of Whether CERC-501 Engages Key Neural Circuitry Related to the Hedonic Response Completed NCT02218736 Phase 2 CERC-501;placebo
43 Effectiveness of Team Treatment of Depression in Primary Care Completed NCT00012766 Phase 2
44 Computerized Information-Processing Bias Retraining in Adolescents With Depression: A Controlled Trial Completed NCT01147913 Phase 2
45 eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients Active, not recruiting NCT02458690 Phase 2 Antidepressant Medications
46 Smoking Cessation Intervention for Depressed Smokers: Treatment Development Active, not recruiting NCT00494728 Phase 1, Phase 2 Nicotine Replacement Therapy
47 eIMPACT-DM Pilot Trial: Depression Treatment to Reduce the Excess Diabetes Risk of People With Depression and Prediabetes Enrolling by invitation NCT04437485 Phase 2 Antidepressant Medications
48 TRIAD Project: Pennsylvania Adolescent Intervention Research Study (PAIRStudy; Project 3a) Terminated NCT00329199 Phase 2
49 A Single-blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks Terminated NCT00206765 Phase 2 Risperidone;Paroxetine
50 An Open Clinical Trial of Interpersonal Psychotherapy for Depressed Adolescence and Parents Completed NCT00619411 Phase 1

Search NIH Clinical Center for Dysthymic Disorder

Cochrane evidence based reviews: dysthymic disorder

Genetic Tests for Dysthymic Disorder

Anatomical Context for Dysthymic Disorder

MalaCards organs/tissues related to Dysthymic Disorder:

40
Testes, Brain, Heart, Breast, Spinal Cord, Eye, Thyroid

Publications for Dysthymic Disorder

Articles related to Dysthymic Disorder:

(show top 50) (show all 2734)
# Title Authors PMID Year
1
Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. 61 54
17346943 2007
2
5-HT2A and 5-HT2C receptors and their atypical regulation properties. 54 61
12650852 2003
3
Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas. 54 61
10357046 1999
4
Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group. 54 61
9347378 1997
5
Moclobemide versus fluoxetine for double depression: a randomized double-blind study. 61 54
9023788 1996
6
Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia. 61 54
7717093 1995
7
5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. 61 54
1903019 1991
8
Feasibility of decision rule-based treatment of comorbid youth: A pilot randomized control trial. 61
32353635 2020
9
Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden of Disease study. 61
31439359 2020
10
The relationship between affective temperament and remission. 61
32558005 2020
11
Predicting the naturalistic course in anxiety disorders using clinical and biological markers: a machine learning approach. 61
32524918 2020
12
Personality and psychiatric disorders in chronic pain male affected by erectile dysfunction: prospective and observational study. 61
32382105 2020
13
From dysthymia to treatment-resistant depression: evolution of a psychopathological construct. 61
32436408 2020
14
Obesity increases the risk of depression in children and adolescents: Results from a systematic review and meta-analysis. 61
32063576 2020
15
Mental disorders on admission to jail: A study of prevalence and a comparison with a community sample in the north of France. 61
32336297 2020
16
Contributing Factors to Heterogeneity in the Timing of the Onset of Nonfatal Suicidal Behavior: Results From a Nationally Representative Study. 61
32271505 2020
17
Perspective: Aristotle on manic-depressive illness and greatness. 61
32276300 2020
18
Internalizing Symptoms in Pediatric Migraine: A Systematic Review Protocol. 61
32096560 2020
19
Self-esteem fully mediates positive life events and depressive symptoms in a sample of 173 patients with affective disorders. 61
30488539 2020
20
Depressive role impairment and subthreshold depression in older black and white women: race differences in the clinical significance criterion. 61
31455459 2020
21
Assessing the Evidence of Micronutrients on Depression among Children and Adolescents: An Evidence Gap Map. 61
32193537 2020
22
[Diagnostics and early recognition of bipolar disorders]. 61
32125440 2020
23
Mental disorders and total mortality after 20 years in an adult general population sample. 61
32115002 2020
24
Brain structure and symptom dimensions in borderline personality disorder. 61
32093800 2020
25
Persistent depressive disorder across the adult lifespan: results from clinical and population-based surveys in Germany. 61
32041560 2020
26
Depression predicts self assessment of social function in both patients with schizophrenia and healthy people. 61
31740212 2020
27
Network structure of depression symptomology in participants with and without depressive disorder: the population-based Health 2000-2011 study. 61
32047972 2020
28
Prevalence and recognition of depressive disorders among Chinese older adults receiving primary care: A multi-center cross-sectional study. 61
31493635 2020
29
Convergence of psychiatric symptoms and restless legs syndrome: A cross-sectional study in an elderly French population. 61
31794908 2020
30
Gut Dysthymia: Paraneoplastic Chronic Watery Diarrhea. 61
31965390 2020
31
Correction to: Factors Associated with Mood Disorder Diagnosis Among a Population Based Cohort of Men and Women Living With and Without HIV in British Columbia Between 1998 and 2012. 61
31820184 2020
32
Effectiveness of an internet-based self-guided program to treat depression in a sample of Brazilian users: a study protocol. 61
32159711 2020
33
Associations Between Psychiatric Disorders and Enuresis in Taiwanese Children: A National Population-Based Study. 61
32110107 2020
34
Anxiety and Depression in Patients with Obstructive Sleep Apnoea before and after Continuous Positive Airway Pressure: The ADIPOSA Study. 61
31805748 2019
35
Evaluation of neuropsychiatric comorbidities and their clinical characteristics in Chinese children with asthma using the MINI kid tool. 61
31752780 2019
36
Effectiveness and Safety of Bupropion in Children and Adolescents with Depressive Disorders: A Retrospective Chart Review. 61
31671492 2019
37
The prevalence of comorbid depression in patients with diabetes: A meta-analysis of observational studies. 61
31790965 2019
38
Validation of the Recent Life Changes Questionnaire (RLCQ) for stress measurement among adults residing in urban communities in Pakistan. 61
31639054 2019
39
A machine learning ensemble to predict treatment outcomes following an Internet intervention for depression. 61
30392475 2019
40
Current pharmacotherapeutic approaches for dysthymic disorder and persistent depressive disorder. 61
31290333 2019
41
Lifestyle interventions for mental health. 61
31569326 2019
42
Sociodemographic Characteristics of Adult Saudi Patients with Mood Disorder Subtypes. 61
31543738 2019
43
Post-traumatic stress reactions among individuals with visual impairments: a systematic review. 61
29644887 2019
44
Factors associated with tobacco consumption in patients with depression. 61
31018000 2019
45
Construction of Disease Similarity Networks Using Concept Embedding and Ontology. 61
31437962 2019
46
[Epidemiological survey of mental disorders in the rural left behind elderly aged 60 years and older in Gansu]. 61
31434422 2019
47
Prevalence of Psychiatric Disorders and Associated Factors among the Youth in Ravansar, Iran. 61
31679346 2019
48
Fibromyalgia and its New Lessons for Neuropsychiatry. 61
31273184 2019
49
Is the association between precarious employment and mental health mediated by economic difficulties in males? Results from two Italian studies. 61
31269944 2019
50
Toward a neurobehavioral trait conceptualization of depression proneness. 61
30950526 2019

Variations for Dysthymic Disorder

Expression for Dysthymic Disorder

Search GEO for disease gene expression data for Dysthymic Disorder.

Pathways for Dysthymic Disorder

GO Terms for Dysthymic Disorder

Cellular components related to Dysthymic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.63 WASF2 WASF1 SLC6A4 HTR2A HTR1A HCRT
2 postsynapse GO:0098794 9.26 WASF3 WASF1 HCRT BDNF
3 SCAR complex GO:0031209 8.8 WASF3 WASF2 WASF1

Biological processes related to Dysthymic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 memory GO:0007613 9.61 SLC6A4 HTR2A BDNF
2 vasoconstriction GO:0042310 9.48 SLC6A4 HTR1A
3 behavior GO:0007610 9.46 HTR2A HTR1A
4 sleep GO:0030431 9.4 HTR2A HCRT
5 dendrite extension GO:0097484 9.37 WASF1 BDNF
6 negative regulation of potassium ion transport GO:0043267 9.32 HTR2A HCRT
7 serotonin receptor signaling pathway GO:0007210 9.26 HTR2A HTR1A
8 modification of postsynaptic actin cytoskeleton GO:0098885 9.16 WASF3 WASF1
9 lamellipodium morphogenesis GO:0072673 8.96 WASF2 WASF1
10 positive regulation of Arp2/3 complex-mediated actin nucleation GO:2000601 8.8 WASF3 WASF2 WASF1

Molecular functions related to Dysthymic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase A regulatory subunit binding GO:0034237 9.33 WASF3 WASF2 WASF1
2 Arp2/3 complex binding GO:0071933 9.13 WASF3 WASF2 WASF1
3 serotonin binding GO:0051378 8.8 SLC6A4 HTR2A HTR1A

Sources for Dysthymic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....